The tumor types with the highest prevalence of KRAS mutations (KRASm) were PDAC (92%), appendiceal adenocarcinoma (61%), small bowel adenocarcinoma (SBA, 53%), CRC (49%), and non-squamous (non-Sq) NSCLC (35%) (Supplemental Table 2); CRC, non-Sq NSCLC, PDAC together represented 71% (63,480/88,907) of the KRASm pan-tumor population (Fig. 1c, d). Here, KRAS is linked to appendix adenocarcinoma.